

## Cyltezo

Kuwait · access guide

# How to access Cyltezo (Humira biosimilar) from Kuwait: 2026 pathway via Mubarak Al-Kabeer, Amiri, and Sabah specialty clinics | Reserve Meds

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Kuwait treats adalimumab populations across rheumatology, dermatology, gastroenterology, ophthalmology at Mubarak Al-Kabeer Hospital, Amiri Hospital, and Sabah Hospital paediatric specialty. The 2026 question for Humira patients is whether to switch to Cyltezo, the FDA interchangeable biosimilar.

## Why Cyltezo, why now

Cyltezo (adalimumab-adbm) was FDA-designated interchangeable with Humira in October 2021. Same indications as reference Humira: RA, JIA (4+), AS, PsA, plaque psoriasis (adult and paediatric 6+), CD (adult and paediatric 6+), UC (adult and paediatric 5+), HS (adult and paediatric 12+), uveitis. SC every other week.

Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic. Other Humira biosimilars include Amjevita, Hyrimoz, Hadlima, Yusimry, and others.

## What Cyltezo is, in plain language

SC adalimumab biosimilar pen or pre-filled syringe, every other week after training. Onset gradual (4-12 weeks). Interchangeable with Humira per FDA designation.

## Eligibility at a Kuwait specialty clinic

Treating specialist confirms indication, screens for hepatitis B, latent TB, active infection. Pregnancy plan documented. Live vaccines updated before initiation. Adult management at Mubarak Al-Kabeer or Amiri; paediatric at Sabah.

## The Kuwait prescribing and supply picture

Cyltezo Kuwait MoH registration status is variable. Where not yet registered, access is via MoH personal-import or Foreign Medical Treatment pathway for Kuwaiti nationals. Reserve Meds coordinates the import file, prescription chain, and cold-chain shipping.

## Cost band

---

USD 40K-60K annual per patient (KWD 12K-18K), lower than reference Humira. MoH coverage under chronic-disease formulary for Kuwaiti nationals; private insurance pre-authorization required.

## What to expect, week-by-week

---

Weeks 0 to 2: confirm indication, screen TB and hepatitis B, prescription, MoH FMT or personal-import filing. Weeks 2 to 4: shipment, clinic-supervised injection 1-2 sessions, training. Weeks 4 to 12: every-other-week SC; partial response week 4, fuller week 12. Month 6 and 12: full reassessment per indication.

## When Cyltezo is the wrong drug

---

Active untreated TB or hepatitis B reactivation risk: treat first. NYHA III-IV heart failure: contraindicated. Demyelinating disease: caution. Active malignancy: contraindicated. Non-response or anti-drug antibodies on prior adalimumab: consider alternative class. Reserve Meds does not promote one TNF biosimilar over another or over the reference biologic.

## Closing

---

Reserve Meds runs the Cyltezo supply file from the Mubarak Al-Kabeer, Amiri, or Sabah specialty referral through MoH FMT or personal-import authorisation and delivered cold-chain supply. Clinical decisions remain with your treating specialist.

### ***Reserve Meds's role***

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com